Meeting
2014 ASCO Annual Meeting
Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.
Authors
Chris Twelves
Leeds Institute of Cancer and Pathology, and St James's Institute of Oncology, Leeds, United Kingdom
Chris Twelves , Javier Cortes , Linda T. Vahdat , Martin S. Olivo , Yi He , Peter Andrew Kaufman , Ahmad Awada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00337103 and NCT00388726
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 631^)
DOI
10.1200/jco.2014.32.15_suppl.631
Abstract #
631^
Poster Bd #
95
Abstract Disclosures
Similar Posters
Poster
2014 Breast Cancer Symposium
Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.
First Author: Peter Kaufman
Poster
2014 Breast Cancer Symposium
Peripheral neuropathy (PN) in patients (pts) with metastatic breast cancer treated with eribulin: Resolution and association with efficacy.
First Author: Peter Kaufman
Poster
2022 ASCO Annual Meeting
A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).
First Author: Se Hyun Kim
Poster
2020 ASCO Virtual Scientific Program
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).
First Author: Santiago Escrivá